Literature DB >> 32516413

Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena.

Leonard J Appleman1.   

Abstract

Mesh:

Substances:

Year:  2021        PMID: 32516413      PMCID: PMC7781442          DOI: 10.1093/jnci/djaa077

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  15 in total

1.  Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.

Authors:  Andrea Necchi; Daniele Raggi; Andrea Gallina; Jeffrey S Ross; Elena Farè; Patrizia Giannatempo; Laura Marandino; Maurizio Colecchia; Roberta Lucianò; Marco Bianchi; Renzo Colombo; Andrea Salonia; Giorgio Gandaglia; Nicola Fossati; Marco Bandini; Filippo Pederzoli; Umberto Capitanio; Francesco Montorsi; Joep J de Jong; Ryan Dittamore; Yang Liu; Elai Davicioni; Joost L Boormans; Alberto Briganti; Peter C Black; Ewan A Gibb
Journal:  Eur Urol       Date:  2020-03-09       Impact factor: 20.096

2.  Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Authors:  Romain Banchereau; Daniel Castellano; Thomas Powles; Mark Kockx; Alejo Rodriguez-Vida; Ignacio Duran; Simon J Crabb; Michiel S Van Der Heijden; Bernadett Szabados; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; Maria Jose Mendez; Cristina Suarez; Mark Linch; Aaron Prendergast; Pieter-Jan van Dam; Diana Stanoeva; Sofie Daelemans; Sanjeev Mariathasan; Joy S Tea; Kelly Mousa
Journal:  Nat Med       Date:  2019-11-04       Impact factor: 53.440

Review 3.  PARP inhibitors: Synthetic lethality in the clinic.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

4.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

5.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

6.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

Review 7.  Treatment of Non-small Cell Lung Cancer with EGFR-mutations.

Authors:  Kazue Yoneda; Naoko Imanishi; Yoshinobu Ichiki; Fumihiro Tanaka
Journal:  J UOEH       Date:  2019

8.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

Authors:  Yohann Loriot; Andrea Necchi; Se Hoon Park; Jesus Garcia-Donas; Robert Huddart; Earle Burgess; Mark Fleming; Arash Rezazadeh; Begoña Mellado; Sergey Varlamov; Monika Joshi; Ignacio Duran; Scott T Tagawa; Yousef Zakharia; Bob Zhong; Kim Stuyckens; Ademi Santiago-Walker; Peter De Porre; Anne O'Hagan; Anjali Avadhani; Arlene O Siefker-Radtke
Journal:  N Engl J Med       Date:  2019-07-25       Impact factor: 91.245

Review 9.  HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.

Authors:  Sonia Pernas; Sara M Tolaney
Journal:  Ther Adv Med Oncol       Date:  2019-03-19       Impact factor: 8.168

10.  Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Authors:  Marco Bandini; Jeffrey S Ross; Daniele Raggi; Andrea Gallina; Maurizio Colecchia; Roberta Lucianò; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Deho'; Siraj M Ali; Russell Madison; Jon H Chung; Andrea Salonia; Alberto Briganti; Francesco Montorsi; Andrea Necchi
Journal:  J Natl Cancer Inst       Date:  2021-01-04       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.